89Zr-DFO-girentuximab Expanded Access Program (EAP)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this Expanded Access Program (EAP) is to enable the use of 89Zr-DFO-girentuximab with positron emission tomography/computed tomography (PET/CT) imaging to non-invasively detect carbonic anhydrase 9 (CAIX)-expressing clear cell renal cell carcinoma (ccRCC) in patients with renal masses as determined by conventional imaging.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC

NCT07077083

Clear Cell Renal Cell Carcinoma (ccRCC) ccRCC

NOT_YET_RECRUITING PHASE2

Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma

NCT02883153

Renal Cell Carcinoma

COMPLETED PHASE2/PHASE3

89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study

NCT03849118

Clear Cell Renal Cell Carcinoma

COMPLETED PHASE3

89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study

NCT06750419

Clear Cell Renal Cell Carcinoma

RECRUITING PHASE3

Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC

NCT04496089

Carcinoma, Renal Cell Clear Cell Renal Cell Carcinoma

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Clear Cell Renal Cell Carcinoma

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

89Zr-DFO-girentuximab

Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written and voluntarily given informed consent.
2. Male or female ≥ 18 years of age.
3. Imaging evidence of renal mass(es) obtained from conventional diagnostic imaging with CT or MRI (without and with contrast enhancement) based on national standards that is not older than 90 days on Day 0, and that was performed before any screening procedure.
4. Negative urine/serum pregnancy tests in female patients of childbearing potential.
5. Consent to practice highly effective contraception until a minimum of 42 days after IV 89Zr-DFO-girentuximab administration.

Exclusion Criteria

1. Renal mass known to be a metastasis of another primary tumor.
2. Active non-renal malignancy requiring therapy during and up to EOT visit.
3. Radiotherapy or immunotherapy within 4 weeks (28 days) prior to the planned administration of 89Zr-DFO-girentuximab or continuing adverse effects (\> grade 1 using Common Terminology Criteria for Adverse Events \[CTCAE\] version 5.0) from such therapy.
4. Planned antineoplastic therapies (for the period between IV administration of 89Zr-DFO-girentuximab and imaging).
5. Previous administration of any radionuclide within 10 of its half-lives before Day 0.
6. Serious non-malignant disease (e.g., psychiatric, infectious, autoimmune, or metabolic), that may interfere with the objectives of the program or with the safety or compliance of the subject, as judged by the Investigator.
7. Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the program.
8. Exposure to any experimental diagnostic or therapeutic drug within 30 days from the date of planned administration of 89Zr-DFO-girentuximab.
9. Women who are pregnant or breastfeeding.
10. Known hypersensitivity to girentuximab or DFO (desferoxamine).

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No